Company to present interim update from ENLIGHTED Phase 3 Study in LG UTUC following assessment of 50% of targeted total ...

About ImPact Biotech ImPact Biotech is an advanced clinical-stage oncology company focused on the development and commercialization of Padeliporfin vascular targeted photodynamic (VTP) therapy ...

MAIA Biotechnology, Inc. (NYSE American ... data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual Meeting of the American Society of Clinical ...

CHICAGO, May 15, 2025--(BUSINESS WIRE)--MAIA Biotechnology ... the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual Meeting of the American Society of ...

Q1 2025 Earnings Call Transcript May 14, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is ...

All three presentations will be held on Monday ... The collaborative approach between NIA and PDS Biotech allows PDS Biotech to focus our resources on our versatile 003 clinical trial.

The Biotechnology Program has also expanded its STEM outreach efforts to include a summer internship program for high school ...

CHICAGO, May 15, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American ... the efficacy data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual ...

ABOUT CARVYKTI® (CILTACABTAGENE AUTOLEUCEL; CILTA-CEL) ...